AZN.UK

12,598

+1.32%↑

GSK

1,620

-1.7%↓

HLN.UK

331.8

+0.58%↑

STJ

1,293

+0.58%↑

HIK

1,841

+0.82%↑

AZN.UK

12,598

+1.32%↑

GSK

1,620

-1.7%↓

HLN.UK

331.8

+0.58%↑

STJ

1,293

+0.58%↑

HIK

1,841

+0.82%↑

AZN.UK

12,598

+1.32%↑

GSK

1,620

-1.7%↓

HLN.UK

331.8

+0.58%↑

STJ

1,293

+0.58%↑

HIK

1,841

+0.82%↑

AZN.UK

12,598

+1.32%↑

GSK

1,620

-1.7%↓

HLN.UK

331.8

+0.58%↑

STJ

1,293

+0.58%↑

HIK

1,841

+0.82%↑

AZN.UK

12,598

+1.32%↑

GSK

1,620

-1.7%↓

HLN.UK

331.8

+0.58%↑

STJ

1,293

+0.58%↑

HIK

1,841

+0.82%↑

Home・Listă Acțiuni・Oxford Biomedica PLC

O
Oxford Biomedica PLC

Închisă

612 3.03

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

585

Maxim

616

Indicatori cheie
By Trading Economics
Venit	-11M
Vânzări	78M
EPS	-0.11
Marjă de profit	-13.726
Angajați	900
EBITDA	5M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+4.59% upside

Statistici piață
By TradingEconomics
Capitalizare de piață	671M
Deschiderea anterioară	608.97
Închiderea anterioară	612

Oxford Biomedica PLC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 oct. 2025, 23:30 UTC

Acțiuni populare

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 oct. 2025, 21:21 UTC

Câștiguri

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 oct. 2025, 00:00 UTC

Achiziții, Fuziuni, Preluări

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 oct. 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 oct. 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 oct. 2025, 23:29 UTC

Achiziții, Fuziuni, Preluări

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 oct. 2025, 23:29 UTC

Achiziții, Fuziuni, Preluări

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 oct. 2025, 23:29 UTC

Achiziții, Fuziuni, Preluări

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 oct. 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 oct. 2025, 22:54 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Scales's JV Buyout Lauded by Bull -- Market Talk

2 oct. 2025, 22:54 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Global Forex and Fixed Income Roundup: Market Talk

2 oct. 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 oct. 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 oct. 2025, 21:17 UTC

Achiziții, Fuziuni, Preluări

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 oct. 2025, 20:50 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Energy & Utilities Roundup: Market Talk

2 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 oct. 2025, 20:49 UTC

Achiziții, Fuziuni, Preluări

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 oct. 2025, 20:00 UTC

Achiziții, Fuziuni, Preluări

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 oct. 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 oct. 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 oct. 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 oct. 2025, 18:46 UTC

Achiziții, Fuziuni, Preluări

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 oct. 2025, 18:46 UTC

Achiziții, Fuziuni, Preluări

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 oct. 2025, 18:46 UTC

Achiziții, Fuziuni, Preluări

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 oct. 2025, 18:45 UTC

Achiziții, Fuziuni, Preluări

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 oct. 2025, 18:45 UTC

Achiziții, Fuziuni, Preluări

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 oct. 2025, 18:44 UTC

Achiziții, Fuziuni, Preluări

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 oct. 2025, 18:44 UTC

Achiziții, Fuziuni, Preluări

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 oct. 2025, 18:44 UTC

Achiziții, Fuziuni, Preluări

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 oct. 2025, 18:43 UTC

Achiziții, Fuziuni, Preluări

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Comparație

Modificare preț

Oxford Biomedica PLC Așteptări

Obiectiv de preț

By TipRanks

4.59% sus

Prognoză pe 12 luni

Medie 617.053 GBX 4.59%

Maxim 930 GBX

Minim 400 GBX

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOxford Biomedica PLC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

4 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 4 analiști care au acordat evaluări ale acțiunilor Oxford Biomedica PLC - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Oxford Biomedica PLC

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.